MME and Hepatic fibrosis: Using this model, we assessed the potential therapeutic impact of combining angiotensin II receptor blocker (valsartan) with neprilysin inhibitor (sacubitril) to alleviate diabetes induced-hyperlipidemia, oxidative stress, inflammation, and hepatic fibrosis.